Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?

Cancer Research

Volumn 58, Issue 11, 1998, Pages 2269-2277

  Zhu, Bao Ting ^a   Conney, Allan H ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b Department of Chemical Biology ^*

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; 4 HYDROXYESTRADIOL; CATECHOL ESTROGEN; CATECHOL METHYLTRANSFERASE; ESTRADIOL RECEPTOR;

BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; HYDROXYLATION; MITOSIS SPINDLE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; ESTRADIOL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED;

EID: 0000317180     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. Clifton, K. H., and Meyer, R. K. Mechanism of anterior pituitary tumor induction by oestrogen. Anat. Rec., 125: 65-81, 1956.
2. Kirkman, H. Estrogen-induced tumors of the kidney in Syrian hamster. III. Growth characteristics in the Syrian hamster. Natl. Cancer Inst. Monogr., 1: 1-57, 1959.
3. Cutts, J. H., and Noble, R. L. Estrone-induced mammary tumors in the rat. I. Induction and behavior of tumors. Cancer Res., 24: 1116-1123, 1964.
4. Newbold, R. R., Bullock, B. C., and MacLachlan, J. A. Uterine adenocarcinoma in mice following developmental treatment with estrogen. Cancer Res., 50: 7677-7681, 1990.
5. Nandi, S., Guzma, R. C., and Yang, J. Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc. Natl. Acad. Sci. USA, 92: 3650-3657, 1995.
6. Yager, J. D., and Liehr, J. G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 36: 203-232, 1996.
7. Li, J. J., and Li, S. A. The effects of hormones on tumor induction. In: J. G. Arcos, M. F. Argus, and Y. T. Woo (eds.), Chemical Induction of Cancer, pp. 396-449. Boston, MA: Birkhauser, 1996.
8. Ziel, H. K., and Finkle, W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med., 293: 1167-1170, 1975.
9. Siiter, P. K., Williams, J. E., and Takaki, N. K. Steroid abnormalities in endometrial and breast carcinoma: a unifying hypothesis. J. Steroid. Biochem., 7: 897-903, 1976.
10. Mack, T. M., Pike, M. C., Henderson, B. E., Pfeffer, R. I., Gerkins, V. R., Arthur, M., and Brown, S. E. Estrogens and endometrial cancer in a retirement community. N. Engl. J. Med., 294: 1262-1267, 1976.
11. McDonald, T. W., Annegers, J. F., O'Fallow, W. M., Dockerty, M. B., Malkasian, G. D., Jr., and Karland, L. T. Exogenous estrogens and endometrial carcinoma: case control and incidence study. Am. J. Obstet. Gynecol., 127: 572-580, 1977.
12. Grady, D., and Ernster, V. L. Endometrial Cancer. In: D. Schottenfeld and J. F. Fraumeni, Jr. (eds.), Cancer Epidemiology and Prevention, Ed. 2, pp. 1058-1089. Oxford: Oxford University Press, 1996.
13. Jick, H., Walker, A. M., Watkins, R. N., D'Ewart, D. C., Hunter, J. R., Danford, A., Madsen, S., Dinan, B. J., and Rothman, K. J. Replacement estrogens and breast cancer. Am. J. Epidemiol., 112: 586-594, 1980.
14. Pike, M. C., Spicer, D. V., Dahmoush, L., and Press, M. F. Estrogens, progestagens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev., 15: 17-35, 1993.
15. Kelsey, J. L., and Gammon, M. D. The epidemiology of breast cancer. CA Cancer J. Clin., 41: 146-165, 1991.
16. Feigelson, H. S., and Henderson, B. E. Estrogens and breast cancer. Carcinogenesis (Lond.), 17: 2279-2284, 1996.
17. Silver, M. A quantitative analysis of the role of oestrogen in mammary development in the rat. J. Endocrinol., 10: 17-34, 1953.
18. Martin, L., Finn, C. A., and Trinder, G. Hypertrophy and hyperplasia in the mouse uterus after estrogen treatment: an autoradiographic study. J. Endocrinol., 56: 133-141, 1973.
19. Banerjee, M. R. Responses of mammary cells to hormones. Int. Rev. Cytol., 4: 1-97, 1976.
20. Quarmby, V. E., and Korach, K. S. Influence of 17β-estradiol on the pattern of cell division in the uterus. Endocrinology, 114: 694-702, 1984.
21. Holland, M. B., and Roy, D. Estrogen-induced cell proliferation and differentiation in the mammary gland of the female Noble rat. Carcinogenesis (Lond.), 16: 1955-1961, 1995.
22. Bradlow, H. L., Hershcopf, R. J., Martucci, C. P., and Fishman, J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc. Natl. Acad. Sci. USA, 82: 6295-6299, 1985.
23. Liehr, J. G., Ulubelen, A. A., and Strobel, H. W. Cytochrome P-450-mediated redox cycling of estrogens. J. Biol. Chem., 261: 16865-16870, 1986.
24. Swaneck, G. E., and Fishman, J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc. Natl. Acad. Sci. USA, 85: 7831-7835, 1988.
25. Liehr, J. G. Genotoxic effects of estrogens. Mutat. Res., 238: 269-276, 1990.
26. Liehr, J. G., and Roy, D. Free radical generation by redox cycling of estrogens. Free Radical Biol. Med., 8: 415-423, 1990.
27. Nutter, L. M., Ngo, E. O., and Abul-Hajj, Y. J. Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. J. Biol. Chem., 266: 16380-16386, 1991.
28. Telang, N. T., Sato, A., Wong, G. Y., Osborne, M. P., and Bradlow, H. L. Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst., 84: 634-638, 1992.
29. Han, X., and Liehr, J. G. 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res., 54: 5515-5517, 1994.
30. Han, X., and Liehr, J. G. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis (Lond.), 15: 997-1000, 1994.
31. Nutter, L. M., Wu, Y-Y., Ngo, E. O., Sierra, E. E., Gutierrez, P. L., and Abul-Hajj, Y. J. An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem. Res. Toxicol., 7: 23-28, 1994.
32. Cavalieri, E. L., Stack, D. E., Devanesan, P. D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S. L., Patil, K. D., Gross, M. L., Gooden, J. K., Ramanathan, R., Cerny, R. E., and Rogan, E. G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA, 94: 10937-10942, 1997.
33. Martucci, C. P., and Fishman, J. P450 enzymes of estrogen metabolism. Pharmacol. Ther., 57: 237-257, 1993.
34. Zhu, B. T., and Conney, A. H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis (Lond.), 19: 1-27, 1998.
35. Axelrod, J., and Tomchick, R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem., 233: 702-705, 1958.
36. Axelrod, J., Albers, W., and Clemente, C. D. Distribution of catechol-O-methyltransferase in the nervous system and other tissues. J. Neurochem., 5: 68-71, 1959.
37. Guldberg, H. C., and Marsden, C. A. Catechol-O-methyltransferase. Pharmacological aspects and physiological role. Pharmacol. Rev., 27: 135-206, 1975.
38. Inoue, K., Tice, L. W., and Creveling, C. R. Immunocytochemical localization of catechol-O-methyltransferase. In: E. Usdin, N. Weiner, and M. B. H. Youdim (eds.), Structure and Function of Monoamine Enzymes, pp. 835-859. New York: Marcel Dekker, 1977.
39. Assicot, M., Contesso, G., and Bohuon, C. Catechol-O-methyltransferase in human breast cancers. Eur. J. Cancer, 13: 961-966, 1977.
40. Amin, A. M., Creveling, C. R., and Lowe, M. C. Immunohistochemical localization of catechol methyltransferase in normal and cancerous breast tissues of mice and rats. J. Natl. Cancer Inst., 70: 337-342, 1983.
41. Thakker, D. R., and Creveling, C. R. O-Methylation. In: G. J. Mulder (ed.), Conjugation Reactions in Drug Metabolism, pp. 193-232. London: Taylor & Francis, Ltd., 1990.
42. Guldberg, H. C., and Marsden, C. A. Catechol-O-methyltransferase. Pharmacological aspects and physiological role. Pharmacol. Rev., 27: 135-206, 1975.
43. Ball, P., and Knuppen, R. Catecholoestrogens (2- and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol., 232: 1-127, 1980.
44. Roy, D., Weisz, J., and Liehr, J. G. The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. Carcinogenesis (Lond.), 11: 459-462, 1990.
45. Zhu, B. T., Roy, D., and Liehr, J. G. The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology, 132: 577-583, 1993.
46. Zhu, B. T., Bui, Q. D., Weisz, J., and Liehr, J. G. Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. Endocrinology, 135: 1772-1779, 1994.
47. Ball, P., and Knuppen, R. Formation, metabolism, and physiologic importance of catecholestrogens. Am. J. Obstet. Gynecol., 163: 2163-2170, 1990.
48. Dunn, J. F. Transport of estrogens in human plasma. In: G. R. Merriam and M. B. Lipsett (eds.), Catechol Estrogens, pp. 167-176. New York: Raven Press, 1983.
49. Fishman, J., and Martucci, C. P. Biological properties of 16α-hydroxyestrone: implications in estrogen physiology and pathophysiology. J. Clin. Endocrinol. Metab., 51: 611-615, 1980.
50. Merriam, G. R., MacLusky, N. J., Picard, M. K., and Naftolin, F. Comparative properties of the catechol estrogens. I. Methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids. 36: 1-11, 1980.
51. Gordon, S, Cantrall, E. W., Cekleniak, W. P., Albers, H. J., Mauer, S., Stolar, S. M., and Bernstein, S. Steroid and lipid metabolism. The hypocholesteremic effect of estrogen metabolites. Steroids, 4: 787-791, 1964.
52. Martucci, C. Induction of rat plasma renin substrate by 2-methoxyestrone. The Endocrine Society 64th Annual Meeting, abstract 889, 1982.
53. Katayama, S., and Fishman, J. 2-Hydroxyestrone suppresses and 2-methoxyestrone augments the preovulatory prolactin surge in the cycling rat. Endocrinology, 110: 1448-1450, 1982.
54. Seegers, J. C., Aveling, M-L., van Aswegen, C. H., Cross, M., Koch, F., and Joubert, W. S. The cytotoxic effects of estradiol-17β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J. Steroid Biochem., 32: 797-809, 1989.
55. Lottering, M-L., Haag, M., and Seegers, J. C. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res., 52: 5926-5932, 1992.
56. D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J., and Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA, 91: 3964-3968, 1994.
57. Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., and Schwelgerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature (Lond.), 368: 217-239, 1994.
58. Cushman, M., He, H. M., Katzenellenbogen, J. A., Lin, C. M., and Hamel, E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem., 38: 2041-2049, 1995.
59. Cushman, M., He, H. M., Katzenellenbogen, J. A., Varma, R. K., Hamel, E., Lin, C. M., Ram, S., and Sachdeva, Y. P. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem., 40: 2323-2334, 1997.
60. Nakagawa-Yagi, Y., Ogane, N., Inoki, Y., and Kitoh, N. The endogenous estrogen metabolite 2-methoxyestradiol induces apoptotic neuronal cell death in vitro. Life Sci., 58: 1461-1467, 1996.
61. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res., 57: 81-86, 1997.
62. Yue, T. L., Wang, X., Louden, C. S., Gupta, S., Pillarisetti, K., Gu, J. L., Hart, T. K., Lysko, P. G., and Feuerstein, G. Z. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol. Pharmacol., 51: 951-962, 1997.
63. Li, J. J., and Li, S. A. Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed. Proc., 46: 1858-1863, 1987.
64. Zhu, B. T., and Liehr, J. G. Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol. Appl. Pharmacol., 125: 149-158, 1994.
65. Zhu, B. T., and Liehr, J. G. Inhibition of catechol O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by quercetin: possible role in estradiolinduced tumorigenesis. J. Biol. Chem., 271: 1357-1363, 1996.
66. Liehr, J. G., Fang, W. K., Sirbasku, D. A., and Ulubelen, A. A. Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid. Biochem., 24: 353-356, 1986.
67. Metzler, M. The metabolism of diethylstilbestrol. CRC Crit. Rev. Biochem., 10: 171-212, 1981.
68. Metzler, M. Biochemical toxicology of diethylstilbestrol. In: E. Hodgson, J. R. Bend, and R. M. Philpot (eds.), Reviews in Biochemical Toxicology, Vol. 6, pp. 191-220. New York: Elsevier, 1984.
69. Gladek, A., and Liehr, J. G. Mechanism of genotoxicity of diethylstilbestrol in vivo. J. Biol. Chem., 264: 16847-16852, 1989.
70. Verma, A. K., Johnson, J. A., Gould, M. N., and Tanner, M. A. Inhibition of 7,12-dimethylbenz[a]anthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res., 48: 5754-5758, 1988.
71. Deschner, E. E., Ruperto, J., Wong, G., and Newmark, H. L. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis (Lond.), 12: 1193-1196, 1991.
72. Zhu, B. T., and Liehr, J. G. Inhibition of the catechol-O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by catecholamines: implications for the mechanism of estrogen-induced carcinogenesis. Arch. Biochem. Biophys., 304: 248-256, 1993.
73. Riley, V. Mouse mammary tumors: alteration of incidence as apparent function of stress. Science (Washington DC), 189: 465-467, 1975.
74. Cooper, C. L. (ed.) Stress and Breast Cancer. New York: John Wiley and Sons, 1988.
75. Faragher, E. B., and Cooper, C. L. Type A stress prone behavior and breast cancer. Psychol. Med., 20: 663-670, 1990.
76. Forsen, A. Psychosocial stress as a risk for breast cancer. Psychother. Psychosom., 55: 176-185, 1991.
77. Green, S., and Watson, M. Towards a psychobiological model of cancer: psychological considerations. Soc. Sci. Med., 20: 773-777, 1985.
78. Aragona, M., Muscatello, M. R., Losi, E., Panetta, S., La Torre, F., Pastura, G., Bertolani, S., and Mesiti, M. Lymphocyte number and stress parameter modifications in untreated breast cancer patients with depressive mood and previous life stress. J. Exp. Ther. Oncol., 1: 354-360, 1996.
79. Cohn, C. K., Dunner, D. L., and Axelrod, J. Reduced catechol-O-methyltransferase activity in red blood cells of women with primary affective disorder. Science (Washington DC), 170: 1323-1324, 1970.
80. Weinshilboum, R. M., Raymond, F. A., Elveback, L. R., and Weidman, W. H. Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature (Lond.), 252: 490-491, 1974.
81. Weinshilboum, R. M., and Raymond, F. A. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am. J. Hum. Genet., 29: 125-135, 1977.
82. Scanlon, P. D., Raymond, F. A., and Weinshilboum, R. M. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science (Washington DC), 203: 63-65, 1979.
83. Weinshilboum, R. Methyltransferase pharmacogenetics. Pharmacol. Ther., 43: 77-90, 1989.
84. Boudíková, B., Szumlanski, C., Maidak, B., and Weinshilboum, R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther., 48: 381-389, 1990.
85. Lundstrom, K., Salminen, M., Jalanko, A., Savolainen, R., and Ulmanen, I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol., 10: 181-189, 1991.
86. Bertocci, Miggiano, V., Parada, M. D., Dembic, Z., Lahm, H-W., and Malherbe, P. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc. Natl. Acad. Sci. USA, 88: 1416-1420, 1991.
87. Tenhunen, J., Salminen, M., Lundstrom, K., Kiviluoto, T., Savolainen, R., and Ulmanen, I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem., 223: 1049-1059, 1994.
88. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y-M., Szumlanski, C. L., and Weinshilboum, R. M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6: 243-250, 1996.
89. Chen, C. H., Lee, Y. R., Liu, M. Y., Wei, F. C., Koong, F. J., Hwu, H. G., and Hsiao, K. J. Identification of a BglI polymorphism of catechol-O-methyltransferase (COMT) gene and association study with schizophrenia. Am. J. Med. Genet., 67: 556-559, 1996.
90. Karayiogou, M., Altemus, M., Galke, B. L., Goldman, D., Murphy, D. L., Ott, J., and Gogos, J. A. Genotype determining low activity catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc. Natl. Acad. Sci. USA, 94: 4572-4575, 1997.
91. Lavigne, J. A., Helzlsouer, K. J., Huang, H-Y., Strickland, P. T., Bell, D. A., Selmin, O., Watson, M. A., Hoffman, S., Comstock, G. W., and Yager, J. D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res., 57: 5493-5497, 1997.
92. Welsch, C. W. Host factors affecting the growth of carcinogen-induced rat mammary carcinoma: a review and tribute to Charles Brenton Muggins. Cancer Res., 45: 3415-3443, 1985.
93. Jordan, V. C., Lababidi, M. K., and Mirecki, D. M. Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OuJ mice. Eur. J. Cancer, 26: 718-721, 1990.
94. Jordan, V. C., Lababidi, M. K., and Langan-Fahey, S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst., 83: 492-496, 1991.
95. Osborne, M. P., Telang, N. T., Kaur, S., and Bradlow, H. L. Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse. Steroids, 55: 114-119, 1990.
96. Bradlow, H. L., Michnovicz, J. J., Telang, N. T., and Osborne, M. P. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis (Lond.), 12: 1571-1574, 1991.
97. Jellinck, P. H., Michnovicz, J. J., and Bradlow, H. L. Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids, 56: 446-450, 1991.
98. Bradlow, H. L., Sepkovic, D. W., Telang, N. T., and Osborne, M. P. Indole-3-carbinol: a novel approach to breast cancer prevention. Ann. NY Acad. Sci., 768: 180-200, 1995.
99. Kojima, T., Tanaka, T., and Mori, H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res., 54: 1446-1449, 1994.
100. Grubbs, C. J., Steele, V. E., Casebolt, T., Juliana, M. M., Eto, I., Whitaker, L. M., Dragnev, K. H., Kelloff, G. J., and Lubet, R. L. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res., 15: 709-716, 1995.
101. Michnovicz, J. J., Hershcopf, R. J., Naganuma, H., Bradlow, H. L., and Fishman, J. Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N. Engl. J. Med., 315: 1305-1309, 1986.
102. Michnovicz, J. J., Naganuma, H., Hershcopf, R. J., Bradlow, H. L., and Fishman, J. Increased urinary catechol estrogen excretion in female smokers. Steroids, 52: 69-83, 1988.
103. Michnovicz, J. J., Hershcopf, R. J., Haley, N. J., Bradlow, H. L., and Fishman, J. Cigarette smoking alters hepatic estrogen metabolism in men: implications for atherosclerosis. Metab. Clin. Exp. 38: 537-541, 1989.
104. MacMahon, B., Trichopoulos, D., Cole, P., and Brown, J. Cigarette smoking and urinary estrogens. N. Engl. J. Med., 307: 1062-1065, 1982.
105. Jensen, J., Christiansen, C., and Rodbro, P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N. Engl. J. Med., 313: 973-975, 1985.
106. Friedman, A. J., Ravnikar, V. A., and Barbieri, R. L. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil. Steril., 47: 398-401, 1987.
107. Baron, J. A. Smoking and estrogen-related disease. Am. J. Epidemiol., 119: 9-22, 1984.
108. Lesko, S. M., Rosenberg, L., Kaufman, D. W., Helmrich, S. P., Miller, D. R., Strom, B., Schottenfeld, D., Rosenshein, N. B., Knapp, R. C., Lewis, J., and Shapiro, S. Cigarette smoking and the risk of endometrial cancer. N. Engl. J. Med., 313: 593-596, 1985.
109. Baron, J. A., Vecchia, C. L., and Levi, F. The antiestrogenic effect of cigarette smoking in women. Am. J. Obstet. Gynecol., 162: 502-514, 1990.
110. Taioli, E., Trachman, J., Chen, X., Sepkovic, D. W., Bradlow, H. L., and Toniolo, P. Correlation of estradiol 2-hydroxylation and breast cancer risk in patients carrying the MSP-1 polymorphism of CYP4501A1. Proc. Am. Assoc. Cancer Res., 37: 249, 1996.
111. Taioli, E., Trachman, J., Chen, X., Toniolo, P., and Garte, S. J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res., 55: 3757-3758, 1995.
112. Bailey, L. R., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., and Parl, F. F. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res., 58: 65-70, 1988.
113. Taioli, E., Garte, S., Trachman, J., Garbers, S., Sepkovic, D. W., Osborne, M. P., Mehl, S., and Bradlow, H. L. Ethnic differences in estrogen metabolism in healthy women. J. Natl. Cancer Inst., 88: 617, 1996.
114. Coker, A. L., Crane, M. M., Sticca, R. P., and Sepkovic, D. W. R. Ethnic differences in estrogen metabolism in healthy women. J. Natl. Cancer Inst., 89: 89-90, 1997.
115. Miller, B. A., Ries, L. A. G., Hankey, B. F., Kosary, C. L., Harris, A., Devesa, S. S., and Edwards, B. K. (eds.). SEER Cancer Statistics Review: 1973-1990, NIH Publication No. 93-2789. Bethesda, MD: National Cancer Institute, 1993.
116. Lipsett, M. B., Merriam, G. R., Kono, S., Brandon, D. D., Pfeiffer, D. G., and Loriaux, D. L. Metabolic clearance of catechol estrogens. In: G. R. Merriam and M. B. Lipsett (eds.), Catechol Estrogens, pp. 105-114. New York: Raven Press, 1983.
117. Emons, G., Merriam, R., Pfeiffer, D., Loriaux, D. L., Ball, P., and Knuppen, R. Metabolism of exogenous 4- and 2-hydroxyestradiol in human male. J. Steroid Biochem., 28: 499-504, 1987.
118. Davies, I. J., Naftolin, F., Ryan, K. J., Fishman, J., and Sin, J. The affinity of catechol estrogens for estrogen receptors in the pituitary and anterior hypothalamus of the rat. Endocrinology, 97: 554-557, 1975.
119. Martucci, C., and Fishman, J. Uterine estrogen receptor binding of catecholestrogens and of estetrol [1,3,5(10)estratriene-3,15α,16α,17β-tetrol]. Steroids, 27: 325-333, 1976.
120. Martucci, C., and Fishman, J. Impact of continuously administered catechol estrogens on uterine growth and LH secretion. Endocrinology, 105: 1288-1292, 1979.
121. Fishman, J. Biological action of catecholestrogens. J. Endocr., 85: 59P-65P, 1981.
122. Schneider, J., Huh, M. M., Bradlow, H. L., and Fishman, J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J. Biol. Chem., 259: 4840-4845, 1984.
123. Vandewalle, B., and Lefebvre, J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol. Cell. Endocrinol., 61: 239-246, 1989.
124. van Aswegen, C. H., Purdy, R. H., and Wittliff, J. L. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptor human breast cancers. J. Steroid Biochem., 32: 485-492, 1989.
125. Schutze, N., Vollmer, G., Tiemann, I., Geiger, M., and Knuppen, R. Catecholestrogens are MCF-7 cell estrogen agonists. J. Steroid Biochem. Mol. Biol., 46: 781-789, 1993.
126. Schutze, N., Vollmer, G., arid Knuppen, R. Catecholestrogens are agonists of estrogen receptor-dependent gene expression in MCF-7 cells. J. Steroid Biochem. Mol. Biol., 48: 453-461, 1994.
127. van Landeghemm, A. A., Poortman, J., Nabuurs, M., and Thijssen, J. H. H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res., 45: 2900-2906, 1985.
128. Santen, R. J. Determinants of tissue oestradiol levels in human breast cancer. Cancer Surv., 5: 597-616, 1986.
129. Hoffman, A. R., Paul, S. M., and Axelrod, J. Catecholestrogen synthesis and metabolism by human breast tumors in vitro. Cancer Res., 39: 4584-4587, 1979.
130. MacLusky, N. J., Naftolin, F., Krey, L. C., and Franks, S. The catechol estrogen. J. Steroid Biochem., 15: 111-124, 1981.
131. Levin, M., Weisz, J., Bui, Q. D., and Santen, R. J. Peroxidatic catecholestrogen production by human breast cancer tissue in vitro. J. Steroid Biochem., 28: 513-520, 1987.
132. Abul-Hajj, Y. J., Thijssen, J. H., and Blankenstein, M. A. Metabolism of estradiol by human breast cancer. Eur. J. Cancer Clin. Oncol., 24: 1171-1178, 1988.
133. Liehr, J. G., and Ricci, M. J. 4-Hydroxylation of estrogens as a marker of human mammary tumors. Proc. Natl. Acad. Sci. USA, 93: 3294-3296, 1996.
134. Williamson, D. G. The biochemistry of the 17-hydroxysteroid dehydrogenases. In: R. Hobkirk (ed.), Steroid Biochemistry, Vol. I, pp. 83-110. Boca Raton, FL: CRC Press, 1979.
135. Poutanen, M., Isomaa, V., Peltoketo, H., and Vihko, R. Regulation of oestrogen action: role of 17β-hydroxysteroid dehydrogenases. Ann. Med., 27: 675-682, 1995.
136. Tseng, L., and Gurpide, E. Changes in the in vitro metabolism of estradiol during the menstrual cycle. Am. J. Obstet. Gynecol., 114: 1002-1008, 1972.
137. Tseng, L., and Gurpide, E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology. 97: 825-833, 1975.
138. Hobkirk, R., and Glasier, M. A. Generation of estradiol within the pregnant guinea pig uterine compartment with special reference to the myometrium. J. Steroid Biochem. Mol. Biol., 44: 291-297, 1993.
139. Poutanen, M., Isomaa, V., Peltoketo, H., and Vihko, R. Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J. Steroid Biochem. Mol. Biol., 55: 525-532, 1995.
140. Luu-The, V., Zhang, Y., Poirier, D., and Labrie, F. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol., 55: 581-587, 1995.
141. Bonney, R. C., Reed, M. J., Davidson, K., Beranek, P. A., and James, V. H. T. The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin. Endocrinol., 19: 727-739, 1983.
142. 3H]oestradiol by normal breast and breast tumour tissue in postmenopausal women. Int. J. Cancer, 38: 193-196, 1986.
143. Vermeulen, A., Deslypere, J. P., Pavidaens, R., Leclevq, G., Roy, F., and Henson, J. C. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in post-menopausal women. Eur. J. Cancer Clin. Oncol., 32: 515-522, 1986.
144. Logan, W. P. D. Marriage and childbearing in relation to cancer of the breast and uterus. Lancet, 2: 1199-1202, 1953.
145. Joly, D. J., Lilienfeld, A. M., Diamond, E. L., and Bross, I. D. J. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am. J. Epidemiol., 99: 190-209, 1974.
146. Pathak, D. R., Speizer, F. E., Willett, W. C., Rosner, B., and Lipnick, R. J. Parity and breast cancer risk: possible effect on age at diagnosis. Int. J. Cancer, 37: 21-25, 1986
147. Kvåle, G., Heuch, I., and Nilssen, S. Reproductive factors and cancers of the breast and genital organs. Are the different cancer sites similarly affected ? Cancer Detect. Prevent., 15: 369-379, 1991.
148. Sherman, B. M., and Korenman, S. G. Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology. Cancer (Phila.), 13: 1306-1311, 1974.
149. Horwitz, K. B., Wei, L. L., Sedlacek, S. M., and d'Arville, C. N. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog. Hormone Res., 41: 249-316, 1985.
150. Mauvais-Jarvis, P., Kuttenn, F., and Gompel, A. Antiestrogen action of progesterone in breast tissue. Hormone Res., 28: 212-218, 1987.
151. Key, T. J. A., and Pike, M. C. The role of estrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Clin. Oncol., 24: 29-43, 1988.
152. Bradlow, H. L., Hershcopf, R. J., and Fishman, J. Oestradiol 16α-hydroxylase: a risk marker for breast cancer. Cancer Surv., 5: 573-583, 1986.
153. Fishman, J., Osborne, M. P., and Telang, N. T. The role of estrogen in mammary carcinogenesis. Ann. NY Acad. Sci., 768: 91-100, 1995.
154. Kabat, G. C., Chang, C. J., Sparano, J. A., Sepkovic, D. W., Hu, X-P., Khalil, A., Rosenblatt, R., and Bradlow, H. L. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol. Biomarkers Prevent., 6: 505-509, 1997.
155. Bradlow, H. L., Telang, N. T., Sepkovic, D. W., and Osborne, M. P. 2-Hydroxyestrone: the "good" estrogen. J. Endocrinol., 150: S259-S265, 1996.
156. Li, J. J., Li, S. A., Oberley, T. D., and Parsons, J. A. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. Cancer Res., 55: 4347-4351, 1995.
157. Lemon, H. M., Heidel, J. W., and Rodriguez-Sierra, J. F. Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer. Cancer (Phila.), 69: 457-465, 1992.
158. Adlercreutz, H., Gorbach, S. L., Goldin, B. R., Woods, M. N., Dwyer, J. T., and Hämäläinen, E. Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl. Cancer Inst., 86: 1076-1082, 1994.
159. Adlercreutz, H., Gorbach, S. L., Goldin, B. R., Woods, M. N., Dwyer, J. T., Höckerstedt, K., Wähälä, K., Hase, T., Hämäläinen, E., and Fotsis, T. Diet and urinary estrogen profile in various populations. A preliminary report. Polycyclic Aromatic Compounds, 6: 261-273, 1994.
160. Attalla, H., Makela, T. P., Adlercreutz, H., and Andersson, L. C. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biophys. Res. Commun., 228: 467-473, 1996.
161. Mukhopadhyay, T., and Roth, J. A. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene, 14: 379-384, 1997.
162. Lottering, M-L., de Kock, M., Viljoen, T. C., Grobler, C. J. S., and Seegers, J. C. 17β-Estradiol metabolites affect some regulators of the MCF-7 cell cycle. Cancer Lett., 110: 181-186, 1996.
163. Seegers, J. C., Lottering, M-L., and De Kock, M. The endogenous metabolites γ-linolenic acid (GLA) and 2-methoxyestradiol (2ME) inhibit cell cycle progression and cause apoptosis induction selectively in tumor cells. Proc. Am. Assoc. Cancer Res., 38: 627, 1997.
164. Markaverich, B. M., and Clark, J. H. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology, 105: 1458-1462, 1979.
165. 3H]estradiol exchange. Endocrinology, 109: 62-69, 1987.
166. Markaverich, B. M., Gregory, R. R., Alejandro, M. A., Clark, J. H., Johnson, G. A., and Middleditch, B. S. Methyl p-hydroxyphenyllactate: an inhibitor of cell proliferation and an endogenous ligand for nuclear type II binding sites. J. Biol. Chem., 263: 7203-7210, 1988.
167. Xu, X., and Thomas, M. L. Biophasic actions of estrogen on colon cancer cell growth: possible mediation by high- and low-affinity binding sites. Endocrine, 3: 661-665, 1995.
168. Fuqua, A., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O'Malley, B. W., and McGuire, W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res., 51: 105-109, 1991.
169. Pfeffer, U., Fecarotta, E., and Vidali, G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and MCF-7 cells. Cancer Res., 55: 2158-2165, 1995.
170. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925-5930, 1996.
171. Laudet, V., Hänni, C., Coll, J., Catzeflis, F., and Stehelin, D. Evolution of the nuclear receptor gene superfamily. EMBO J., 11: 1003-1012, 1992.
172. Soontjens, C. D., Rafter, J. J., and Gustafsson, J-Å. Ligands for orphan receptors? J. Endocrinol., 150: S241-S257, 1996.